logo
ProjectClosed

SKiN-HUID

One of 5,497 projects Taiyo tracks in Belgium.

Source: Keep.EU

Cancer is one of the most threatening diseases of this century, causing eight million deaths worldwide each year. Cancer's complexity means the disease can only be treated through innovation and translating knowledge into new medication. Under the direction of the University of Maastricht, the University of Antwerp, Basic Pharma Technologies, MosaMedix and VIB are seeking to meet the specific chal

Status
Closed
Sector
Education, Hospital, Power Generation (CCGT), Government, Consumer Products, Bridge, Hotel
Location
Belgium
Updated
22 Jul 2026
Source
Keep.EU

ConstructChat

Ask ConstructChat about SKiN-HUID

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “SKiN-HUID” is an infrastructure initiative in the Education sector, located in Belgium. Taiyo aggregates data on it from Keep.EU.

Participants

Sponsoring Agency

Status

Original status

Closed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Cancer is one of the most threatening diseases of this century, causing eight million deaths worldwide each year. Cancer's complexity means the disease can only be treated through innovation and translating knowledge into new medication. Under the direction of the University of Maastricht, the University of Antwerp, Basic Pharma Technologies, MosaMedix and VIB are seeking to meet the specific challenges of cancer. At Euregional PACT, a virtual research laboratory set up through the previous Interreg programme, a number of basic medical technologies have already been developed at academic level. One of those technologies is the Anx-A5-based platform for Target Drug Delivery. It involves targeted administration of medicines via electrical or hypothermic stimulation, which exerts stress on the cells. Advantages of this technique are the efficient, targeted coupling of toxic pharmaceutical quantities, but on the basis of reduced doses so that general side-effects remain limited and the patient's quality of life is maintained. The aim is to further expand this technology within SKiN-HUID into a therapy, through preclinical and clinical validation. A stimulation device with applicator will be developed that is to be used for preclinical validation of the treatment. The Annexine A5-ETA-based medicine is also being further developed to enable targeted, efficient administration by means of the device and the applicator.

Budget

Location

Country

Belgium

Source

Source reliability

Medium

Source

Keep.EU

URL

More Details

Record type

Project

Sector

Education, Hospital, Power Generation (CCGT), Government, Consumer Products, Bridge, Hotel

Article published date

2023-07-05

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project